In 2025, China Resources Jiangzhong Pharmaceutical Co., Ltd. achieved operating revenue of RMB 4.22 billion, representing a year-on-year decrease of 4.87%. The net profit attributable to shareholders of the listed company reached RMB 906 million, marking a 14.96% increase compared to the previous year. During the reporting period, despite facing pressures from industry structural adjustments, China Resources Jiangzhong Pharmaceutical persistently strengthened its brand building efforts. It focused on solidifying the foundation of its core business by concentrating on "major products and strong categories." Furthermore, the company diversified its marketing strategies, enhanced investment returns, and optimized its expense structure. It also deepened its commitment to lean manufacturing, advancing cost reduction and efficiency improvements, which collectively contributed to the enhancement of its profitability level.